91 related articles for article (PubMed ID: 22084448)
1. Time course of treatment effect of OROS® methylphenidate in children with ADHD.
Armstrong RB; Damaraju CV; Ascher S; Schwarzman L; O'Neill J; Starr HL
J Atten Disord; 2012 Nov; 16(8):697-705. PubMed ID: 22084448
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
3. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Silva RR; Brams M; McCague K; Pestreich L; Muniz R
Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
5. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
[TBL] [Abstract][Full Text] [Related]
8. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
Wigal SB; Childress AC; Belden HW; Berry SA
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
11. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
[No Abstract] [Full Text] [Related]
12. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
Golubchik P; Kodesh A; Weizman A
Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
[TBL] [Abstract][Full Text] [Related]
13. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
Kim E; Cheon KA; Joung YS; Kim JY; Song DH
Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
[TBL] [Abstract][Full Text] [Related]
14. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
Katzman MA; Sternat T
CNS Drugs; 2014 Nov; 28(11):1005-33. PubMed ID: 25120227
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
Childress AC; Brams M; Cutler AJ; Kollins SH; Northcutt J; Padilla A; Turnbow JM
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
[TBL] [Abstract][Full Text] [Related]
16. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
Kollins SH; Braeckman R; Guenther S; Barrett AC; Mickle TC; Oh C; Marraffino A; Cutler AJ; Brams MN
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):597-609. PubMed ID: 34714120
[No Abstract] [Full Text] [Related]
18. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
Gormez V; Avery B; Mann H
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
